Pharma Mar, S.A.

Informe acción BME:PHM

Capitalización de mercado: €549.3m

Pharma Mar Dirección

Dirección controles de criterios 1/4

El CEO de Pharma Mar's es Jose Fernandez Sousa-Faro, nombrado en Jan 1986, tiene una permanencia de 38.25 años. posee directamente un 6.32% de las acciones de la empresa, con un valor de €29.55M. La antigüedad media del equipo directivo y de la junta directiva es de 13.1 años y 1.8 años, respectivamente.

Información clave

Jose Fernandez Sousa-Faro

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO38.3yrs
Participación del CEO6.3%
Permanencia media de la dirección13.2yrs
Promedio de permanencia en la Junta Directiva1.9yrs

Actualizaciones recientes de la dirección

Recent updates

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

CEO

Jose Fernandez Sousa-Faro

38.3yrs

Permanencia

€294,000

Compensación

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Jose Fernandez Sousa-Faro
Founder38.3yrs€294.00k6.32%
€ 34.7m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00ksin datos
Juan Carretero
Founderno datasin datossin datos
María de Francia Caballero
Chief Financial Officer24.3yrssin datossin datos
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations9.3yrssin datossin datos
Juan Pulido
General Counsel & Secretary of the Board of Directors4.7yrssin datossin datos
Sandra Sanchez
Global Compliance Head4yrssin datossin datos
Lara Vadillo
Communication Directorno datasin datossin datos
Belén Veramendi
Director of Corporate Development2.3yrssin datossin datos
Luis Cuenca
Director of Human Resources & IT20.8yrssin datossin datos
Luis Mora Capitan
Managing Director of Oncology & Virology Business Units17.1yrssin datossin datos
Pascal Besman
Chief Operating Officer of Pharmar U.S.no datasin datossin datos

13.2yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de PHM es experimentado (13.1 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.32%
€ 34.7m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00ksin datos
Eduardo Serra Rexach
Independent Other External Director3.3yrs€35.00k0.062%
€ 342.9k
M. Solchaga Catalan
Independent Other External Directorno data€35.00ksin datos
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.41%
€ 29.7m
Blanca Hernandez Rodriguez
Independent Director5.3yrssin datossin datos
Maria Sandra Mera
Representative Proprietary Director3.4yrssin datossin datos
Rosa Maria Alonso
Independent Director1.9yrssin datos0.0010%
€ 5.7k
Mariano Rodriguez
Independent Coordinating Director1.9yrssin datossin datos
Emiliano Aller
Independent Director1.9yrssin datossin datos
Fernando Santos
Independent Other External Directorno datasin datossin datos
Soledad Miranda
Independent Directorless than a yearsin datossin datos

1.9yrs

Permanencia media

Junta con experiencia: La junta directiva de PHM no se considera experimentada (1.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.